MedTrace Logo

Effects of Personalized Digital Reminiscence Therapy on Patients With Neurocognitive Disorders

NCT07237009 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2026-03-09

No results posted yet for this study

Summary

This study aims to observe the effects of daily personalized digital reminiscence sessions, conducted with the help of a digital conversational agent, and to determine whether these sessions lead to improvements in symptoms such as apathy and depression.

The researchers therefore seek to observe whether this daily use can improve certain aspects of well-being, such as motivation, mood, sleep quality, quality of life, and engagement with the tool.

The study also aims to assess whether simple reminders delivered via the application are sufficient to encourage regular use without external assistance.

Participants will:

* Use the reminiscence app for 25 days for 10-15 minutes.
* Have a primary caregiver help personalize the app by sharing family memories, other relatives may optionally contribute in a private group.
* Complete brief questionnaires at the start and during follow-up routine visits (for example, apathy and depression scales, sleep, and quality of life).

Conditions

  • Neurocognitive Disorders, Mild
  • Cognitive Impairment, Mild
  • Depression Mild
  • Apathy
  • Apathy in Dementia

Sponsors & Collaborators

  • Clinical Research Units Hungary

    collaborator OTHER

  • KompanionCare SAS

    lead INDUSTRY

Principal Investigators

  • Cédric Annweiler, Geriatrician, PhD neuroscience · Angers University Hospital Center

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-14
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07237009 on ClinicalTrials.gov